E2F1 Expression predicts outcome in korean women who undergo surgery for breast carcinoma

Annals of Surgical Oncology

Volumn 17, Issue 2, 2010, Pages 564-571

  Kwon, Mi Jung ^a   Nam, Eun Sook ^a   Cho, Seong Jin ^a   Park, Hye Rim ^a   Shin, Hyung Sik ^a   Park, Jun Ho ^a   Park, Chan Heun ^a   Lee, Won Jae ^b  

^a Hallym University   (South Korea)

^b Department of Rehabilitation Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; E2F1 TRANSCRIPTION FACTOR; E2F2 TRANSCRIPTION FACTOR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KOREA; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 77149126742     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0767-z     Document Type: Article

References (28)

1. JH Lee SH Yim YJ Won KW Jung BH Son HD Lee, et al. 2007 Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival J Korean Med Sci 22 S11 S16 10.3346/jkms.2007.22.S.S11 17923736
2. G Argarwal PV Pradeep V Aggarwal CH Yip P Ceung 2007 Spectrum of breast cancer in Asian women World J Surg. 31 1031 1040 10.1007/s00268-005-0585-9 (Pubitemid 46716756)
3. PA Greenberg GN Hortobagyi TL Smith, et al. 1996 Long-term follow-up of patients with complete emission following combination chemotherapy for breast cancer J Clin Oncol. 14 2197 2205 1:CAS:528:DyaK28XltFSqsLk%3D 8708708
4. R Chopra 2001 The Indian scene J Clin Oncol. 19 18 106 110
5. SA Khan MA Rogers KK Khurana MM Mequid PJ Numann 1998 Estrogen receptor expression in benign breast epithelium and breast cancer risk J Natl Cancer Inst. 90 37 42 10.1093/jnci/90.1.37 1:STN:280:DyaK1c%2FovFSmtQ%3D%3D 9428781
6. NE Kushlinskii ES Gershtein 2001 Modern prospects for molecular-biochemical methods for evaluating biological "behavior" of breast neoplasms Vestn Ros Akad Med Nauk. 9 65 70
7. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet. 365 60 62 10.1016/S0140-6736(05)74803-0 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 15639680
8. EP Winer C Hudis HJ Burstein AC Wolff KI Pritchard JN Ingle, et al. 2005 American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol. 23 619 629 10.1200/JCO.2005.09.121 1:CAS:528:DC%2BD2MXitVartb4%3D 15545664 (Pubitemid 46224240)
9. CJ Sherr 1996 Cancer cell cycles Science. 274 1672 1677 10.1126/science.274.5293.1672 1:CAS:528:DyaK28XntlyktLs%3D 8939849 (Pubitemid 26414890)
10. C Stevens NB La Thangue 2003 E2F and cell cycle control: a double-edged sword Arch Biochem Biophys. 412 157 169 10.1016/S0003-9861(03)00054-7 1:CAS:528:DC%2BD3sXit1KmsL8%3D 12667479 (Pubitemid 36344139)
11. C Attwooll E Lazzerini Denchi K Helin 2004 The E2F family: specific functions and overlapping interests EMBO J. 23 4709 4716 10.1038/sj.emboj. 7600481 1:CAS:528:DC%2BD2cXhtVGitr%2FL 15538380 (Pubitemid 40069701)
12. NB La Thangue 2003 The yin and yang of E2F1: balancing life and death Nat Cell Biol. 5 587 589 10.1038/ncb0703-587 1:CAS:528:DC%2BD3sXkvFerur8%3D 12833056 (Pubitemid 36818074)
13. JY Lee CK Park JO Park T Lim YS Park HY Lim, et al. 2008 Impact of E2F1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy Clin Cancer Res. 14 82 88 10.1158/1078-0432.CCR-07-0612 1:CAS:528:DC%2BD1cXoslOr 18172256
14. O Belvedere F Puglisi C Di Loreto P Cataldi A Guglielmi C Aschele, et al. 2004 Lack of correlation between immunohistochemical expression of E2F1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer Ann Oncol. 15 55 58 10.1093/annonc/mdh018 1:STN:280:DC%2BD3srps1Kmsg%3D%3D 14679120 (Pubitemid 38139604)
15. SH Han KM Park BN Bae KH Kim HJ Kim YD Kim, et al. 2003 E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide Breast Cancer Res Treat. 82 11 16 10.1023/B:BREA.0000003843.53726.63 1:CAS:528: DC%2BD3sXptVCgsrs%3D 14672398 (Pubitemid 37476014)
16. EY Kim HJ Jo MJ Lee 2005 Expressions of E2F4 and E2F2 transcription factors in breast carcinoma Korean J Pathol. 39 301 306
17. AD Saiz M Olvera S Rezk BA Florentine A McCourty RK Brynes 2002 Immunohistochemical expression of cyclin D1, E2F1, and Ki-67 in benign and malignant thyroid lesions J Pathol. 198 157 162 10.1002/path.1185 1:CAS:528:DC%2BD3sXivV2jsr8%3D 12237874 (Pubitemid 35243873)
18. B Eymin S Gazzeri 2001 Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumours: E2F1 is up-regulated in small cell lung carcinoma Oncogene 20 1678 1687 10.1038/sj.onc.1204242 1:CAS:528: DC%2BD3MXivFKhsLY%3D 11313916 (Pubitemid 32368015)
19. SY Zhang SC Liu LF Al-Saleem D Holloran J Babb X Guo, et al. 2000 E2F1: a proliferative marker of breast neoplasia Cancer Epidemiol Biomarkers Prev. 9 395 401 1:CAS:528:DC%2BD3cXjt1Cks7w%3D 10794484
20. JY Kim HW Kim KU Choi CH Lee MY Sol HJ Kang, et al. 2006 Alteration of G1/S cell cycle regulatory proteins in ovarian epithelial tumors Korean J Pathol. 40 274 281
21. P Zacharators A Kotsinas K Evangelou P Karakaidos LV Vassiliou N Rezaei, et al. 2004 Distinct expression patterns of the transcription factor E2F1 in relation to tumour growth parameters in common human carcinomas J Pathol. 203 744 753 10.1002/path.1582 (Pubitemid 38961560)
22. F Rabbani VM Richon I Orlow ML Lu M Drobnjak M Dudas, et al. 1999 Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization J Natl Cancer Inst. 91 874 881 10.1093/jnci/91.10.874 1:STN:280:DyaK1M3ntVOmtA%3D%3D 10340908
23. GH Ho JE Calvano M Bisogna KJ Van Zee 2001 Expression of E2F1 and E2F4 is reduced in primary and metastatic breast carcinomas Breast Cancer Res Treat. 69 115 122 10.1023/A:1012230115173 1:CAS:528:DC%2BD38XisV2itw%3D%3D 11759817 (Pubitemid 33079018)
24. L Verlinden I Vanden Bempt G Eelen M Drijkoningen I Verlinden K Marchal, et al. 2007 The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER2- breast carcinomas Cancer Res. 67 6574 6581 10.1158/0008-5472.CAN-06-3545 1:CAS:528:DC%2BD2sXnslOjtro%3D 17638866
25. M Pruschy C Wirbelauer C Glanzmann S Bodis W Krek 1999 E2F1 has properties of a radiosensitizer and its regulation by cyclin A kinase is required for cell survival of fibrosarcoma cells lacking p53 Cell Growth Differ. 10 141 146 1:CAS:528:DyaK1MXhvFyhtLw%3D 10099827
26. MJ Elliott MR Farmer C Atienza Jr A Stilwell YB Dong HL Yang, et al. 2002 E2F1 gene therapy induces apoptosis and increases chemosensitivity in human pancreatic carcinoma cells Tumour Biol 23 2 76 86 10.1159/000059708 1:CAS:528:DC%2BD38Xlt1ylsLc%3D 12065845 (Pubitemid 34639109)
27. L Yamasaki 1999 Balancing proliferation and apoptosis in vivo: the goldilocks theory of E2F/DP action Biochim Biophys Acta. 1423 M9 M15 1:CAS:528:DyaK1MXhvVCnsbg%3D 10214348
28. L Yamasaki T Jacks R Bronson E Goillot E Harlow NJ Dyson 1996 Tumor induction and tumor atrophy in mice lacking E2F1 Cell. 85 537 548 10.1016/S0092-8674(00)81254-4 1:CAS:528:DyaK28XjtFyit70%3D 8653789 (Pubitemid 26157192)